Literature DB >> 12020623

Cardiovascular and thrombophilic risk factors for central retinal vein occlusion.

Domenico Prisco1, Rossella Marcucci, Laura Bertini, Anna Maria Gori.   

Abstract

Retinal vein occlusion (RVO) is a relatively common disease that is often associated with a variety of systemic disorders including arterial hypertension, diabetes mellitus, dyslipidemia, and systemic vasculitis. There are various types of RVO, categorized on the basis of the site of occlusion and on the type of consequent vascular damage. Central retinal vein occlusion (CRVO) is the most frequently occurring and clinically relevant type of RVO. In addition to the well-known classical risk factors, new hemostasis-related ones have been investigated in patients affected by CRVO. The data concerning a number of parameters remain contradictory; yet, high levels of type 1 plasminogen activator inhibitor (PAI-1) and hyperhomocysteinemia appear to play a significant role in the pathogenesis of this disease. Although based on a limited number of studies, this new knowledge could eventually provide important indications regarding prognosis and therapeutic strategies.

Entities:  

Year:  2002        PMID: 12020623     DOI: 10.1016/s0953-6205(02)00025-0

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  12 in total

1.  [Multiple thrombophilic risk markers in patients ≺65 years of age with retinal vein occlusion].

Authors:  C Kuhli-Hattenbach; P Hellstern; W Miesbach; T Kohnen; L-O Hattenbach
Journal:  Ophthalmologe       Date:  2017-12       Impact factor: 1.059

2.  Retinal vein occlusion: evaluation of "classic" and "emerging" risk factors and treatment.

Authors:  Marina Turello; Samantha Pasca; Roberto Daminato; Patrizia Dello Russo; Roberta Giacomello; Ugo Venturelli; Giovanni Barillari
Journal:  J Thromb Thrombolysis       Date:  2010-05       Impact factor: 2.300

3.  Effect of oral niacin on central retinal vein occlusion.

Authors:  Michael W Gaynon; Yannis M Paulus; Ehsan Rahimy; Janet L Alexander; Sam E Mansour
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-02-04       Impact factor: 3.117

Review 4.  Retinal vein occlusions: a review for the internist.

Authors:  Rossella Marcucci; Francesco Sofi; Elisa Grifoni; Andrea Sodi; Domenico Prisco
Journal:  Intern Emerg Med       Date:  2010-12-14       Impact factor: 3.397

Review 5.  Review: The Development of Risk Factors and Cytokines in Retinal Vein Occlusion.

Authors:  Yi Tang; Yan Cheng; Shuo Wang; Yongjie Wang; Pengjia Liu; Hong Wu
Journal:  Front Med (Lausanne)       Date:  2022-06-15

6.  Antithrombotic treatment of retinal vein occlusion: a position statement from the Italian Society on Thrombosis and Haemostasis (SISET).

Authors:  Francesco Paciullo; Emanuele Valeriani; Angelo Porfidia; Marcello Di Nisio; Marco P Donadini; Rossella Marcucci; Domenico Prisco; Carlo Cagini; Paolo Gresele; Walter Ageno
Journal:  Blood Transfus       Date:  2022-01-21       Impact factor: 5.752

7.  Vitamin B12 levels in patients with retinal vein occlusion and their relation with clinical outcome: a retrospective study.

Authors:  Francesco Paciullo; Paola Santina Menduno; Davide Tucci; Anna Caricato; Carlo Cagini; Paolo Gresele
Journal:  Intern Emerg Med       Date:  2022-01-14       Impact factor: 5.472

8.  A longitudinal analysis of risk factors associated with central retinal vein occlusion.

Authors:  Maxwell S Stem; Nidhi Talwar; Grant M Comer; Joshua D Stein
Journal:  Ophthalmology       Date:  2012-11-20       Impact factor: 12.079

9.  Homocysteine, MTHFR C677T gene polymorphism, folic acid and vitamin B 12 in patients with retinal vein occlusion.

Authors:  Paola Ferrazzi; Pierpaolo Di Micco; Ilaria Quaglia; Lisa Simona Rossi; Alessandro Giacco Bellatorre; Giorgio Gaspari; Lidia Luciana Rota; Corrado Lodigiani
Journal:  Thromb J       Date:  2005-09-07

10.  Increased expression of angiogenic and inflammatory proteins in the vitreous of patients with ischemic central retinal vein occlusion.

Authors:  Christoph Ehlken; Bastian Grundel; Daniel Michels; Bernd Junker; Andreas Stahl; Günther Schlunck; Lutz L Hansen; Nicolas Feltgen; Gottfried Martin; Hansjürgen T Agostini; Amelie Pielen
Journal:  PLoS One       Date:  2015-05-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.